FDA's latest warning letters in the dietary supplement sector are examples of firms failing to document corrective actions to achieve good manufacturing practices compliance and expecting contract manufacturers to shoulder their GMP burden.
A May 12 letter to Central Point, Ore., firm VitaPurity Corp. and a May 16 letter...





